Cite
Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
MLA
Atsushi Musha, et al. “Concurrent Chemoradiotherapy with Conventional Fractionated Radiotherapy and Low-Dose Daily Cisplatin plus Weekly Docetaxel for T2N0 Glottic Cancer.” Radiation Oncology, vol. 12, Feb. 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....781f3ce594181a0c588eb75b6beae8e6&authtype=sso&custid=ns315887.
APA
Atsushi Musha, Masato Shino, Kazuaki Chikamatsu, Masumi Imaeda, Katsuyuki Shirai, Takashi Nakano, Katsumasa Takahashi, Yukihiro Takayasu, Takanori Abe, & Jun-ichi Saitoh. (2017). Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer. Radiation Oncology, 12.
Chicago
Atsushi Musha, Masato Shino, Kazuaki Chikamatsu, Masumi Imaeda, Katsuyuki Shirai, Takashi Nakano, Katsumasa Takahashi, Yukihiro Takayasu, Takanori Abe, and Jun-ichi Saitoh. 2017. “Concurrent Chemoradiotherapy with Conventional Fractionated Radiotherapy and Low-Dose Daily Cisplatin plus Weekly Docetaxel for T2N0 Glottic Cancer.” Radiation Oncology 12 (February). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....781f3ce594181a0c588eb75b6beae8e6&authtype=sso&custid=ns315887.